The medication is applied across therapeutic domains involving distressing symptoms of acute pain and fever.

---

Management of Acute Symptoms and Discomfort

The therapy is commonly used to help manage mild to moderate pain and is relevant for easing symptoms related to physical discomfort that often appear suddenly, such as following surgical procedures. It supports the management of moderate to severe pain by playing a role as an adjunctive analgesic, which contributes to easing the overall symptom load when used as part of a combined regimen. This approach is applied across domains where additional symptomatic support is needed.

---

Targeted Management of Systemic Imbalance

The therapy also addresses symptoms related to systemic imbalance, specifically managing fever. It offers symptomatic relief that helps patients cope more steadily with difficult episodes characterized by this physiological strain. The medication assists with maintaining functional stability and supports efforts to ease the burden of symptoms. This is commonly used across conditions presenting with acute episodes where symptomatic temperature support is appropriate.

---

Therapeutic Focus: Acute Discomfort and Fever

Eligibility Map: Who Can and Cannot Use Ofirmev

The eligibility for intravenous acetaminophen (Ofirmev) is defined by official regulatory documents, primarily based on contraindications and physiological status.

---

Eligibility Scope

Classification	Status	Rationale (Official Labeling)
Populations Contraindicated	Must Not Use	Severe hepatic impairment, severe active liver disease, or known hypersensitivity to acetaminophen or excipients.
Age-Related Rules	Restricted/Established	Use is established in adults and pediatric groups, including full-term neonates. Effectiveness for acute pain is not established in pediatric patients younger than two years.
Condition-Specific Rules	Conditional Use	Caution is required for patients with hepatic impairment (non-severe), severe renal impairment (CrCl le 30 mL/min), chronic alcoholism, chronic malnutrition, or severe hypovolemia.
Reproductive Status	Conditional Use	Use during pregnancy is permissible only if clearly needed. Caution should be exercised when administered to a nursing woman.

---

Eligibility Classifications (High-Level)

Category	Definition	Regulatory Basis
Contraindicated	Absolute prohibition	Severe hepatic disease, hypersensitivity.
Use with Caution	Risk assessment required	Renal impairment, alcoholism, malnutrition, hypovolemia.
Use Not Established	Insufficient data	Acute pain treatment for pediatric patients < 2 years.

The regulatory structure defines absolute non-eligibility based on severe liver disease or hypersensitivity. All other populations may be eligible, but use is restricted by specific age limitations and requires caution when comorbidities like severe renal impairment or risk factors for hepatotoxicity are present, as stated in the official prescribing information.

Interactions with other medicines and products

Official regulatory documents describe specific interactions and incompatibility constraints for Ofirmev (acetaminophen injection).

Pharmacodynamic and Pharmacokinetic Interactions

Interacting Substance/Class	Interaction Statement	Constraint Type
Oral Anticoagulants (e.g., Sodium Warfarin)	Chronic oral use of high-dose acetaminophen has been associated with an increase in International Normalized Ratio (INR).	Use with Caution
CYP2E1 Inducers/Regulators	Substances that affect the hepatic enzyme CYP2E1 may alter acetaminophen metabolism, potentially increasing hepatotoxic risk.	Risk Management

Physical Incompatibility and Administration Restrictions

Specific restrictions apply to the co-administration of Ofirmev with other intravenous solutions:

• Do not administer simultaneously with Diazepam or Chlorpromazine hydrochloride due to documented physical incompatibility.
• Do not add other medications to the Ofirmev solution.

Population-Specific Interaction Notes

Certain patient conditions increase the susceptibility to adverse outcomes, which impacts the management of potential drug interactions:

• Caution is advised in patients with alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment (creatinine clearance le 30 mL/min).

Central Modulation of Temperature and Pain Signaling

The mechanism of action is primarily executed within the Central Nervous System (CNS). The drug acts as an inhibitor of the Cyclooxygenase ( COX) enzyme system in the brain, a process that decreases the synthesis of the mediator Prostaglandin E2 ( PGE2) in the hypothalamic temperature center. This action contributes to the modulation of the hypothalamic thermoregulatory set point.

Simultaneously, a key metabolite works to modulate ascending pain signaling at the spinal level. This modulation involves the activation of TRPV1 receptors and interaction with the endocannabinoid system, which collectively increases the resistance of the nociceptive pathway to activation.

Mechanistic Specificity and Rapid Action

The mechanism exhibits high central specificity, functioning robustly in the low-peroxide CNS environment but resulting in only marginal inhibition of COX activity in peripheral, high-peroxide environments. The intravenous formulation ensures rapid achievement of high concentration in the CNS and Cerebrospinal Fluid (CSF). This speed of delivery is a mechanism-dependent factor that facilitates the rapid engagement of the thermoregulatory and nociceptive modulation cascades.

General Principles of Administration

Ofirmev is a sterile solution intended for administration strictly via Intravenous (IV) Infusion. This is the sole approved route for this specific formulation. Standard administration protocols specify that each dose be administered slowly and consistently, over a period of 15 minutes.

Dosing Schedules and Limits

The dosage is primarily determined by the patient's weight and age, with all maximum daily limits accounting for acetaminophen intake from any source. For adults and adolescents weighing 50 kg or more, two standard regimens are utilized: 1000 mg administered every 6 hours or 650 mg administered every 4 hours. The maximum total daily dose of acetaminophen from all routes combined is restricted to 4000 mg in a 24-hour period.

Population-Specific Use and Adjustments

For patients weighing less than 50 kg, including all pediatric patients, dosing is calculated using a weight-based regimen (e.g., 15 mg/kg or 12.5 mg/kg). Although the weight-based amount is standardized, the minimum dosing interval varies by age group; for instance, neonates and infants require a minimum of 6 hours between doses. Clinical protocols also indicate that patients with severe renal impairment (CrCl le 30 mL/min) may necessitate longer dosing intervals and a reduced total daily dose.

Preparation and Procedural Constraints

Accurate dose preparation requires aseptic technique. Doses less than 1000 mg must be aseptically withdrawn from the vial and transferred to a separate sterile container for infusion. It is required that the medicine be administered within 6 hours of the original container's seal being penetrated or the contents transferred. No other medications are to be added to the Ofirmev solution or the infusion device itself.

Research Evidence / Overview of Studies for Ofirmev

---

Evidence for Use in Acute Pain Management (Mild to Moderate)

Research exploring short-term randomized controlled trials (RCTs) has primarily focused on the use of intravenous (IV) acetaminophen in contexts of mild to moderate acute pain. These studies monitored patient-reported outcomes, such as changes in pain intensity scores and the total need for additional pain medication (rescue analgesics) over the initial 24 to 48 hours following surgery. Studies comparing the IV form to the common oral form of acetaminophen sometimes reported similar short-term outcomes related to these pain measurements. Follow-up durations were limited in these core studies, meaning there is limited information for long-term outcomes regarding sustained pain monitoring.

Evidence for Use as an Adjunct in Severe Pain Regimens

Research has also explored the use of IV acetaminophen as a component of a multimodal treatment plan intended for moderate to severe pain, typically alongside opioid pain relievers. Studies reported measurements of total opioid medication consumed in patient groups receiving the combination compared to those receiving only an opioid plus a placebo. Studies monitored pain intensity scores in the observed populations when the IV drug was included. Findings were observed to vary across different types of surgical procedures, suggesting that the measured outcomes may vary widely depending on the clinical context.

Evidence for Use in Fever Reduction

The use of IV acetaminophen in research exploring fever was evaluated in RCTs that monitored physiological strain, specifically elevated body temperature. Trials reported measurements of both the absolute change in body temperature and the time required for that change to occur after the infusion. Data show patterns related to the time to onset of temperature change in the short period following drug administration. Research is limited to documenting the symptomatic effect of lowering temperature; studies generally do not evaluate the long-term resolution of the underlying medical condition causing the fever.

Research for Special Populations and Age Groups

For the youngest patients, specifically infants and neonates (under age 2 years), dedicated pharmacokinetic (PK) studies were conducted. Research provided context to inform appropriate recommendations for its use in this group. However, clinical outcomes for pain management in this age group are based primarily on extrapolation and modeling using the PK data, meaning there is limited information derived from dedicated clinical outcome studies in infants and neonates.

Current Evidence Gaps and Areas of Uncertainty

Data for certain groups remain insufficient, especially dedicated clinical outcome trials specifically for neonates and infants. Furthermore, the certainty remains low regarding sustained effects, as long-term effects are not fully established by the existing research.

Key Studies & References Opioid-Sparing Effects of IV Acetaminophen for Patients Undergoing Surgery (Systematic Review/Rapid Review)

Common questions about Ofirmev (FAQ)

Q: What is the official warning regarding the use of Ofirmev with alcohol?

Regulatory documents state that patients who consume three or more alcoholic drinks per day are advised to use acetaminophen products with caution. Official product information suggests that severe liver problems have been associated with high doses of acetaminophen, especially in patients who consume alcohol excessively. This general caution applies as Ofirmev is an acetaminophen product.

Q: Can I use Ofirmev while pregnant or breastfeeding?

Regulatory documents indicate that use during pregnancy should occur only after careful consideration of the benefits and risks. Regarding breastfeeding, available data indicate that acetaminophen passes into breast milk, and official information suggests that use by a breastfeeding mother is often deemed compatible with infant feeding.

Q: What are the recommended administration conditions for Ofirmev?

This medication is a sterile solution intended only for intravenous (IV) infusion. It is administered strictly in a hospital or clinical setting by a healthcare professional. The dose, timing, and rate of infusion are managed entirely by the healthcare team in the clinical setting.

Q: Does Ofirmev make you sleepy?

Official product information lists certain effects on the central nervous system (CNS) as possible adverse reactions. Specifically, temporary dizziness and somnolence (sleepiness) have been reported in clinical studies. Patients experiencing these effects during or after treatment may wish to discuss them with their healthcare provider.

How to Store and Dispose of Ofirmev?

Ofirmev (acetaminophen injection) must be stored and handled according to specific rules to maintain product stability and ensure proper disposal.

---

Official Storage Conditions

• Temperature: Store at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C are permitted.
• Handling: The solution must not be refrigerated or frozen. Examine the container for leaks and do not use the solution if discoloration or particulate matter is present.

Stability and Disposal

• In-Use Limit: Once the container seal is compromised, the product must be administered within 6 hours.
• Disposal: Ofirmev is a single-use product; any unused portion remaining in the container must be discarded in accordance with local pharmaceutical waste regulations.
• Child Safety: Keep the medicine out of the sight and reach of children.